You are betting that a company this deeply in debt will in these circumstances get cheaper credit, will get credit at all, and will have the growing revenues in a world recession to support the debt load. Absolutely brilliant analysis. IMHO.
Myl just swapps $500M debt to very low interest rate. Big pharms can have revenues greatly affected not because of decreasing demand but because of generics competetion. There's no way that Myl's revenue will go down because the demand for generics is increasing, especially in hard economic times. It's people like you who are stupid enough to believe the shorts, and aid them in unwarranted attack of the stock.